DeVIC chemotherapy is effective for patients with refractory or relapsed diffuse large B-cell lymphoma

Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab.

A Case Report of a Metastatic Primary Gastric Lymphoma; Diffuse Large B-Cell or Burkitt Lymphoma?

Introduction: Primary gastric lymphoma (PGL) is a rare tumor, whose differential diagnosis may become complicated without precise immunohistochemistry (IHC) and genetic analysis. Case Presentation: A 33-year-old woman presented with gastric cancer and had undergone gastrectomy without precise IHC and staging in another center. Inappropriate IHC after surgery showed diffuse large B-cell lymphom...

A Case Report of a Metastatic Primary Gastric Lymphoma; Diffuse Large B-Cell or Burkitt Lymphoma?

Introduction: Primary gastric lymphoma (PGL) is a rare tumor, whose differential diagnosis may become complicated without precise immunohistochemistry (IHC) and genetic analysis. Case Presentation: A 33-year-old woman presented with gastric cancer and had undergone gastrectomy without precise IHC and staging in another center. Inappropriate IHC after surgery showed diffuse large B-cell lymphom...

BCL2 Family Related Genes Expression and Chemotherapy Response in Diffuse Large B-Cell Lymphoma

  Background and Objective: Approximately half of patients with diffuse large B-cell lymphoma are cured with current chemotherapy regimens. The purpose of this study was to evaluate Bax and Bcl2 expression and their relationship with the response to chemotherapy. Materials and Methods This study was a prospective analysis on 44 patients with diffuse large B-cell lymphoma. Their specimens we...

Measurement of pyruvate dehydrogenase enzyme in patients with diffuse large B-cell lymphoma relapse

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL), which is the most common type of lymphoma. NHL comprises a group of clinically and biologically diverse diseases, which range from indolent to aggressive clinical courses. Despite treatment advances in the last three decades with the use of combination immunotherapy, a significant fraction...